ERBB2 and neoplasm: In 2009, a supplement to the 2007 ASCO/CAP guidelines defined HER2 heterogeneity as the presence of 5% to 50% of total tumor cells with HER2 gene amplification (HER2/CEP17 ratios of more than 2.2) [69].